Iovance Biotherapeutics (0JDK) Stock Statistics & Valuation Metrics

Iovance Biotherapeutics has a market cap or net worth of $3.74B. The enterprise value is $6.43B.

Market Cap

$3.74B

Enterprise Value

$6.43B

Iovance Biotherapeutics has 462,655,150 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

462,655,150

Owned by Insiders

0.33%

Owned by Institutions

33.62%

Iovance Biotherapeutics’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -50.86%.

Return on Equity (ROE)

-0.56

Return on Assets (ROA)

-0.43

Return on Invested Capital (ROIC)

-50.86%

Return on Capital Employed (ROCE)

-0.51

Revenue Per Employee

270.26K

Profits Per Employee

-401.00K

Employee Count

975

Asset Turnover

0.29

Inventory Turnover

3.35

The current PE Ratio of Iovance Biotherapeutics is -15.26. Iovance Biotherapeutics’s PEG ratio is -0.16.

PE Ratio

-15.26

PS Ratio

9.88

PB Ratio

4.54

Price to FCF

-17.32

Price to Operating Cash Flow

-19.42

PEG Ratio

-0.16

In the last 12 months, Iovance Biotherapeutics had revenue of 263.50M and earned -390.98M in profits. Earnings per share was -1.09.

Revenue

263.50M

Gross Profit

90.32M

Operating Income

-398.21M

Pretax Income

-393.05M

Net Income

-390.98M

EBITDA

-350.89M

Earnings Per Share (EPS)

-1.09

In the last 12 months, operating cash flow was -189.95M and capital expenditures -26.11M, giving a free cash flow of -216.06M billion.

Operating Cash Flow

-189.95M

Free Cash Flow

-216.06M

Free Cash Flow per Share

-0.47

Iovance Biotherapeutics pays an annual dividend of $0.29, resulting in a dividend yield of ―

Dividend Per Share

$0.29

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-5.78%

Earnings Yield

-5.99%

Beta

0.87

52-Week Price Change

209.73%

50-Day Moving Average

11.39

200-Day Moving Average

6.03

Relative Strength Index (RSI)

34.12

Average Volume (3m)

139.37K

Iovance Biotherapeutics upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 05, 2026

Next Earnings Date

Mar 02, 2027

Ex-Dividend Date

Mar 15, 2022

Iovance Biotherapeutics as a current ratio of 3.20, with Debt / Equity ratio of 6.93%

Current Ratio

3.20

Quick Ratio

2.83

Debt to Market Cap

0.00

Net Debt to EBITDA

0.33

Interest Coverage Ratio

0.00

In the past 12 months, Iovance Biotherapeutics has paid -2.07M in taxes.

Income Tax

-2.07M

Effective Tax Rate

0.01

Iovance Biotherapeutics EV to EBITDA ratio is -20.11, with an EV/FCF ratio of -17.23.

EV to Sales

9.82

EV to EBITDA

-20.11

EV to Free Cash Flow

-17.23

EV to Operating Cash Flow

-19.60

Iovance Biotherapeutics has $376.32M in cash and marketable securities with $45.21M in debt, giving a net cash position of $331.11M billion.

Cash & Marketable Securities

$376.32M

Total Debt

$45.21M

Net Cash

$331.11M

Net Cash Per Share

$0.72

Tangible Book Value Per Share

$1.21

Gross margin is 53.23%, with operating margin of -60.79%, and net profit margin of -58.19%.

Gross Margin

53.23%

Operating Margin

-60.79%

Pretax Margin

-58.52%

Net Profit Margin

-58.19%

EBITDA Margin

-48.84%

EBIT Margin

-60.18%

The average price target for Iovance Biotherapeutics is $14.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$14.80

Price Target Upside

84.42% Upside

Analyst Consensus

Strong Buy

Analyst Count

10

Revenue Growth Forecast

51.31%

EPS Growth Forecast

56.78%

Smart Score

10

AI Score

―